Five scientists and engineers have been awarded the 2026 Richard N. Merkin Prize in Biomedical Technology for their contributions to the development of the modern cochlear implant.
The award recognises Graeme Clark, Erwin Hochmair, Ingeborg Hochmair, Michael Merzenich and Blake Wilson. The $400,000 prize is administered by the Broad Institute and will be shared among the five recipients.
This is relevant because the cochlear implant is one of the most significant examples of biomedical engineering moving from experimental research into everyday clinical care. It was the first medical device to interface with the nervous system to provide a sense of hearing.
Cochlear implants are designed for people with severe or complete hearing loss caused by damage to or absence of cochlear hair cells. Unlike hearing aids, which amplify sound, cochlear implants bypass damaged hair cells and electrically stimulate the auditory nerve.
The award highlights several complementary advances. Ingeborg and Erwin Hochmair developed an early microelectronics multi-channel cochlear implant in Vienna. Graeme Clark’s work in Australia contributed to multi-channel stimulation and speech understanding. Michael Merzenich helped establish the neurophysiological basis and safety of cochlear implant design in the United States.
Blake Wilson later advanced signal-processing strategies through continuous interleaved sampling, which helped improve speech understanding for cochlear implant users. This was a key step in moving the technology from experimental use into wider clinical practice.
More than one million people have received cochlear implants worldwide. The technology has also influenced development of other neural prostheses, including emerging approaches for vision and motor function.
The story reflects how medical device innovation often requires decades of cross-disciplinary work across neuroscience, engineering, behavioural science, surgery and clinical validation. It also shows the importance of translating basic research into technologies that can be manufactured, implanted, programmed and supported in real-world healthcare systems.
Future progress in hearing implants will depend on access, affordability, surgical capacity, long-term device support and continued improvement in sound processing. The broader industry lesson is that high-impact biomedical technologies often emerge when engineering and biology are developed together over sustained timelines.
